IndustryCompany release

Elite Pharmaceuticals second-quarter revenue rises 10.4% to $40.1m on own-label amphetamine and naltrexone

🇺🇸 Elite Pharmaceuticals Inc /Nv/ (ELTP) · Thu 12 Nov 2026

The OTCQB-listed niche generics maker reported higher revenue and operating income for the quarter to 30 September 2026, with net income of $17.3m attributable to common shareholders.

Elite Pharmaceuticals, a US niche generic drug manufacturer traded on the OTCQB under the symbol ELTP, published results on 12 November 2026 for the quarter ended 30 September 2026, the second quarter of its 2027 fiscal year.

Revenue came to $40.1m, an increase of $3.8m on the same period a year earlier, which corresponds to growth of 10.4%. The company attributed the rise to sales of its own-label amphetamine and naltrexone products.

Operating income reached $9.9m, up about 21% year over year. Net income attributable to common shareholders was $17.3m. The summary available does not break down what lay behind the gap between operating and net income, and no further detail on margins, product-level sales or guidance was provided.

Elite has scheduled a conference call for 13 November 2026, where management is expected to discuss the figures.

What it means for your team

  • Growth at Elite is led by its own-label products, a point for market-access teams tracking competition in generic amphetamine and naltrexone supply.
  • Quality and supply-chain teams working with contract manufacturers may wish to note that the company's results rest on a small number of key products.
  • The 13 November call may offer more detail on product mix and outlook; the figures reported so far are limited to headline revenue and income.

Company's press release (SEC filing): Elite Pharmaceuticals Inc /Nv/ ↗

Article written by VigiEye from the official source (Elite Pharmaceuticals Inc /Nv/). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →